Evidence map›Paper›PMID 39516677›Full record

ArticleBJC reports2024

PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma.

Minggui Pan, Maggie Y Zhou, Chen Jiang, Zheyang Zhang, Nam Bui, Jeffrey Bien, Amanda Siy, Ninah Achacoso, Aleyda V Solorzano, Pam Tse and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Minggui Pan *Division of Research, Kaiser Permanente, Oakland, CA, 94612, USA. minggui@stanford.edu.
Maggie Y Zhou *Sarcoma Program, Division of Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Chen JiangDivision of Research, Kaiser Permanente, Oakland, CA, 94612, USA.
Zheyang ZhangState Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, 361102, China.
Nam BuiSarcoma Program, Division of Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Jeffrey BienSarcoma Program, Division of Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Amanda SiySarcoma Program, Division of Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Ninah AchacosoDivision of Research, Kaiser Permanente, Oakland, CA, 94612, USA.
Aleyda V SolorzanoDivision of Research, Kaiser Permanente, Oakland, CA, 94612, USA.
Pam TseDivision of Research, Kaiser Permanente, Oakland, CA, 94612, USA.
Elaine ChungDivision of Research, Kaiser Permanente, Oakland, CA, 94612, USA.
Wenwei HuRutger's Cancer Institute of New Jersey, New Brunswick, NJ, 08903, USA.
Sachdev ThomasDepartment of Oncology and Hematology, Kaiser Permanente, Vallejo, CA, 94589, USA.
Kristen GanjooSarcoma Program, Division of Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Laurel A HabelDivision of Research, Kaiser Permanente, Oakland, CA, 94612, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to examine whether PTEN pathogenic variants (mutPTEN) were associated with overall survival (OS) in patients with advanced soft tissue sarcoma (STS) with the presence of one or more of the most common genomic alterations including p53, CDKN2A, RB1, and ATRX pathogenic variants.

methodsThis study included patients from Kaiser Permanente Northern California and Stanford Cancer Center with grade 2 or higher locally advanced and metastatic STS.

resultsA total of 174 patients had leiomyosarcoma (LMS), 136 had undifferentiated pleomorphic sarcoma (UPS), 78 had Liposarcoma (LPS), and 214 had other histology subtypes (Others). Among all patients with STS, OS was worse for those with mutPTEN versus wild-type PTEN (wtPTEN, adjusted HR [aHR] = 1.58 [95% CI, 1.11-2.23]), mutCDKN2A vs wtCDKN2A (aHR = 1.33 [95% CI .99-1.80]), and mutRB1 vs wtRB1 (aHR = 1.26 [95% CI 0.93-1.70[), while OS was similar for mutp53 vs wtp53 and mutATRX vs wtATRX. MutPTEN versus wtPTEN was consistently associated with worse OS in histologic subtypes including LMS and UPS and molecular subgroups.

conclusionMutPTEN vs wtPTEN was associated with worse OS in advanced STS. If confirmed, our findings could be helpful for prognostic stratification in clinical practice and for further understanding the molecular mechanisms of STS.

Identifiers

PMID39516677
PMCPMC11524139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.